Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Larazotide (AT1001) for the Treatment of Long COVID in Children and Adults

NCT05747534 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT05747534
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05747534 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Larazotide (AT1001) for the Treatment of Long COVID in Children and Adults
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2023
Completion date
June 18, 2026
Enrollment
107 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

long covid, long covid-19, post acute covid-19 syndrome, post acute sequelae of covid-19